In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global Vaccines: A Shot Of Growth For GSK And Pfizer?

Executive Summary

Recent M&A activity in the vaccine industry has narrowed the pool of players. For companies that remain, the opportunity to reshape their positions in the global market comes with an even greater responsibility to contribute meaningfully to continued advances in global public health.

You may also be interested in...

Genocea Aims To Take The T-Cell Century By The Horns

Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.

GSK Acquires Conjugated Vaccine Expertise With GlycoVaxyn Purchase

The technology could speed the development of prophylactic and therapeutic conjugated vaccines against difficult-to-treat bacterial infections, and the two companies are planning an innovative collaboration that will see GlycoVaxyn retain its autonomy and agility.

Novartis Revamps, Buys GSK Cancer Drugs, Sells Animal Health To Lilly

Novartis is overhauling its pharma business by exchanging selected assets with GlaxoSmithKline and divesting its animal health business to Eli Lilly. Worth more than $25 billion, the complex corporate deal will boost the Swiss group’s oncology unit and create a consumer health joint venture, while divesting its vaccine unit to GSK.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts